CAR-T Meeting 2021 | Highlights from the 3rd European CAR T-cell Meeting
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, shares her highlights from the 3rd European CAR T-cell meeting. Dr Sureda found particularly interesting the sessions on CAR T-cell-related toxicities, patient-reported outcomes, and academic production of CAR T-cell products. In addition, Dr Sureda outlines the importance and value of the EBMT/EHA CAR T-cell meeting, which is the ideal environment to hear the latest updates in CAR T-cell therapy in Europe, but it also provides a global perspective. This interview took place during the 3rd European CAR T-cell Meeting.
Transcript (edited for clarity)
The sessions looking at more detailed analysis on toxicity of CAR-T were especially interesting. Of course, all these sessions that were dedicated in some ways to patients and looking at patient-related outcomes were also very interesting. And of course, all the development being made by the academia regarding CAR T-cell outside, let’s say pharma companies, I think that they were also very interesting...
The sessions looking at more detailed analysis on toxicity of CAR-T were especially interesting. Of course, all these sessions that were dedicated in some ways to patients and looking at patient-related outcomes were also very interesting. And of course, all the development being made by the academia regarding CAR T-cell outside, let’s say pharma companies, I think that they were also very interesting. I would say that in general, the meeting that unfortunately had to be done in a virtual format this year, and really it’s already a classic. I think that it has become a classic meeting, having an excellent overview of CAR T-cells, not only from a European perspective but of course from a global perspective.
Read more...
Disclosures
Honoraria from Gilead Kite, Novartis and Celgene/BMS
